Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr Lalchandani Labs Ltd has submitted its Annual Report for FY 2024-25 along with the notice for its 8th Annual General Meeting, scheduled for September 30, 2025, in New Delhi. The company, a NABL-accredited diagnostic lab operating since 1986 with 5 labs and 15 collection centers across Delhi/NCR, reported FY25 revenue of ₹446.13 Lakhs and net profit of ₹41.72 Lakhs. Key business items at the AGM include adoption of financial statements, re-appointment of Chairman Arjan Lalchandani (retiring by rotation), re-appointment of Whole-Time Director Mohit Lalchandani for 5 years at ₹14.4 Lakhs per annum, appointment of Mohan Lal Gandhi as Independent Director, and appointment of Chauhan Pradeep & Associates as Secretarial Auditors for 5 years. Importantly, the company is seeking shareholder approval to increase its authorized share capital from ₹4.5 Crores to ₹11 Crores (creating 65 lakh additional equity shares of ₹10 each), signaling plans for future fundraising or expansion. The capital clause of the Memorandum of Association will also be amended accordingly.
The authorized capital hike from ₹4.5 Cr to ₹11 Cr is a forward-looking signal suggesting the company is preparing to raise fresh equity to fund business expansion, which could lead to equity dilution for existing shareholders if shares are eventually issued. FY25 financials remain modest at ₹4.46 Cr revenue and ₹41.7 lakh profit, so any fundraising will need to demonstrate a clear growth path to justify dilution.